Objective: Gemcitabine was approved for the treatment of biliary tract cancer in 2006 in Japan. While biliary tract cancer is usually associated with patients 70 years of age or older and/or those who tend to have underlying liver dysfunction, data on this population were limited in the Japanese Phase II study of gemcitabine. Thus, further evaluation of safety and effectiveness in this population was planned. This special post-marketing surveillance was conducted as an observational study on the use of gemcitabine in a clinical practice setting. Methods: Gemcitabine-naïve patients with biliary tract cancer were enrolled from 2006 to 2008 and observed over 12 months; one or more doses of gemcitabine were administered during the period. Data such as patient background, treatment details, adverse events occurring during the observational period, laboratory values of liver enzyme and survival status were collected 3 and 12 months after the start of therapy. Results: Of the 285 patients registered for the study, 260 were included in the analysis. The mean age was 66.9 years. There were 120 patients (46.2%) classified as elderly (70 years or older). Haematotoxicities were the most common adverse drug reactions. In the elderly and the non-elderly, adverse drug reactions (serious) occurred in 48.3% (20.8%) and 50.7% (12.9%), respectively. The overall estimated 1-year survival rate was 52.5% (95% confidence interval, 45.9 -58.7%). Conclusions: In line with previous clinical and post-marketing studies conducted in Japan, the results of this study suggest that gemcitabine could be used safely and effectively for biliary tract cancer patients including the elderly.
INTRODUCTION
Biliary tract cancer (BTC) is a rare type of cancer in Western countries, but is relatively common in Japan and East Asia (1) . According to demographic statistics compiled by the Japanese Ministry of Health, Labour and Welfare (MHLW), in 2009 a total of 17 599 people in Japan died of BTC, making it the seventh leading cause of death by cancer, and the rate continues to increase gradually. Patients with BTC can achieve long-term survival only when it is curatively resectable. However, as most of the patients with BTC are diagnosed at an advanced stage, the 5-year survival rate was reported to be just above 10% (2) .
Gemcitabine (Gemzar w Injection) is one of the most active medications for BTC as was shown in a Japanese Phase II study of gemcitabine monotherapy (3) . In this study, gemcitabine was shown to be safe with a median survival time of 7.6 months and a 1-year survival rate of 25.0%. Although BTC is more prevalent among the elderly according to demographic statistics compiled by MHLW, in the Japanese Phase II study, only six patients were elderly (aged 70 years or older), which limited the information that could be obtained from this population.
A characteristic factor of the disease is that many patients with BTC suffer from cholestasis requiring biliary drainage (4) . In addition, in the Japanese Phase II study, compared with the results from other Japanese clinical studies for non-small-cell lung cancer and pancreatic cancer, the incidence of hepatic function abnormalities such as increased alanine aminotransferase (ALT) and increased gammaglutamyl transpeptidase (g-GTP) was higher, whereas the incidence of myelosuppression was similar. This indicates that patients with BTC are at high risk for liver dysfunction associated with the primary disease, thereby requiring a study to evaluate whether the administration of gemcitabine can lead to increased onset or worsening of hepatic dysfunction in particular.
Given this background, we conducted an observational study based on post-marketing surveillance (PMS) on the use of gemcitabine in Japanese clinical practice. This was primarily to evaluate the incidence of serious hepatic dysfunction in patients with BTC, and secondly, to compare the incidence of adverse drug reactions between the elderly and non-elderly, and to examine the survival time. This report presents the results of our study.
PATIENTS AND METHODS

CONTRACT WITH INSTITUTIONS
The survey was conducted in compliance with the Japanese regulatory requirements stipulated in the Good Post-marketing Study Practice guidelines. To participate in this study, a medical institution had to be purchasing gemcitabine. A contract could only be signed with such institutions. Prior to the contract, medical representatives of Eli Lilly Japan K.K. visited the survey physicians of those institutions; explained the survey objectives, target patient population, survey methods and other necessary information; obtained an agreement from the potential survey physician and made a request to the head of the institution for the survey.
REGISTRATION
Patients were registered through a central registration system entrusted to Quintiles Transnational Japan K.K. To register a patient, the physicians who were to treat BTC patients with gemcitabine completed a registration form with the necessary information prior to or within 1 week following the initial dosing of gemcitabine to the patient and sent it by fax to the registration centre. The registration period was from 1 July 2006 to 31 March 2008.
PATIENTS
Subjects were diagnosed with BTC according to the General Rules for Surgical and Pathological Studies on Cancer of the Biliary Tract (the 5th edition) (5), and were naive to gemcitabine. All subjects received at least one dose of gemcitabine in this survey.
OBSERVATIONAL PERIOD
The observational period was 12 months or until 30 days after the discontinuation of gemcitabine treatment if discontinued. Survey data were collected at 3 and 12 months of therapy, and at the end of the observational period if the discontinuation of gemcitabine therapy was revealed via the case report forms completed by the attending physicians. Although monitoring was not conducted, the sponsor confirmed inconsistent data with a query sheet. This observational survey was conducted under the conditions of routine clinical practice. Treatment was based on the judgement of the attending physician, without any intervention by the sponsor.
SAFETY ASSESSMENT
Adverse events that occurred during the observational period were collected regardless of causality to the drug. The actual events described were based on each investigator's judgement. Seriousness was assessed by the attending physicians in accordance with the seriousness criteria in the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) guideline. An adverse event was serious if it met at least one of the following criteria: (i) resulted in death, (ii) was life-threatening, (iii) required inpatient hospitalization or prolongation of existing hospitalization, (iv) resulted in persistent or significant disability/incapacity, (v) led to a congenital anomaly/birth defect or (vi) any other medically important condition.
In patients who discontinued gemcitabine therapy, the reason for discontinuation was also collected. In line with Japanese regulations, an adverse drug reaction was defined as an adverse event for which causality to the drug cannot be ruled out.
With regard to liver function tests, data on any jaundice and liver function [total bilirubin (T-Bil), aspartate aminotransferase (AST), ALT, alkaline phosphatase (ALP), lactate dehydrogenase (LDH) and g-GTP] available from routine clinical care were collected monthly (allowable range, + 2 weeks) from the start of therapy to the end of the observational period. As for liver function test values, grading was performed in accordance with the National Cancer Institute Common Terminology Criteria for Adverse Events ver. 3.0 (6). Values showing a higher grade after the start of gemcitabine therapy compared with baseline were regarded as indicating worsening. For all worsened test values, investigations were conducted to determine the presence or absence of worsening of the primary disease and liver metastasis, and whether bile-duct drainage was performed. Post-marketing surveillance of gemcitabine with 260 Japanese BTC patients
EFFECTIVENESS ASSESSMENT
Survival status was investigated at 12 months from the start of gemcitabine therapy. If a patient was deceased, the date and the cause of death were recorded. Any data reported by investigators on patient status after 12 months was also used for the assessment. In patients for whom the survival status could not be confirmed because of transfer to another hospital or other reasons, the date of discontinuation or last dosing whichever was later, was used as the date of last confirmation of survival for the purpose of analysis. These were treated as censored data.
For the carcinoembryonic antigen (CEA) and CA19-9 tumour markers, data available from routine clinical care were collected monthly (+2 weeks) from the start of therapy to the end of the observational period. In patients who had a baseline CEA or CA19-9 value two times or more the upper limit of the reference range (i.e. CEA 5 ng/ ml, CA19-9 37 U/ml), the values after the start of therapy were compared with the baseline ones.
STATISTICAL ANALYSIS
The percentage of patients who experienced adverse drug reactions was calculated. The survival data was analysed using the Kaplan -Meier method.
For CEA and CA19-9, patients were sorted according to the value change after the start of therapy (i.e. decreased by 50% or more, decreased by ,50% or increased), and the number and the percentage of patients in each group were calculated.
Subgroup analyses of safety were performed for elderly/ non-elderly patients, and for patients with/without hepatic dysfunction at the starting point of gemcitabine treatment. Subgroup analyses of survival data were performed for each of the following variables: sex, age, Eastern Cooperative Oncology Group performance status (PS), complications (hepatic function disorder and cholestatic jaundice), prior therapy (bile-duct drainage), primary region of BTC, reason for GEM treatment and stage. Figure 1 shows the disposition of patients. Of the 285 patients registered, case report forms were collected for 284 patients. Of these, 260 patients were included in the analysis after exclusion of those previously treated with gemcitabine (4 patients), those registered but given no dose of gemcitabine (4 patients) and those who did not have BTC [16 patients with intrahepatic bile duct cancer were excluded from analysis based on the General Rules for the Surgical and Pathological Studies on Cancer of the Biliary Tract (5)]. Table 1 summarizes patients' characteristics. Of the 260 patients included in the analysis set, 53.1% were male. The mean age was 66.9 years (29 -87 years). Elderly patients had a mean age of 75.3 years and accounted for 46.2% of analysed patients. The baseline PS was 0 or 1 in 93.8% of the patients. Primary lesion sites included the extrahepatic bile duct (52.7%), gallbladder (38.5%) and papilla (7.3%). Investigators reported patient disease stage before GEM treatment for 212 cases. Disease stages IVa and IVb were reported in 22.6 and 51.4% of patients, respectively. Recurrent cases were not included in the evaluation of disease stages. Patients were grouped by reason for GEM treatment: unresectable BTC, post-non-curative resection of BTC, post-operative adjuvant chemotherapy for BTC, postoperative recurrent BTC and other. Advanced/recurrent disease, which included unresectable, post-non-curative resection and post-operative recurrent BTC, was reported in 75.3% of the patients.
RESULTS
BASELINE CHARACTERISTICS
Comparison of major patient background factors in elderly vs. non-elderly patients showed that for males, 57.5% were elderly and 49.3% non-elderly, baseline PS scores in elderly vs. non-elderly patients were 0 in 66.7 vs. 75.7% and 1 in 25.8 vs. 19.3%, respectively. Respective percentages for the primary lesion site were 57.5 vs. 48.6% (extrahepatic bile duct), 35.0 vs. 41.4% (gallbladder) and 7.5 vs. 7.1% ( papilla). Among 93 elderly and 119 non-elderly patients, after exclusion of those with post-operative recurrence, the disease stage at enrolment was IVa in 28.0 vs. 18.5% and IVb in 48.4 vs. 53.8%, respectively. Advanced/recurrent disease was reported in 82.1% elderly patients vs. 69.6% non-elderly patients.
TREATMENT ADMINISTRATION
Patient treatment is summarized in Table 2 . The mean duration of the observational period was 184.2 days (median, 174.0 days; range: 29 -420 days), mean number of doses 13.6 (median, 11.5 doses; range: 1 -40 doses) and mean dose 816.3 mg/m 2 (median, 856.1 mg/m 2 ; range: 115 -1053 mg/ m 2 ). Concomitant therapy was given to 90 patients (34.6%); the most common therapies were bile-duct drainage (68 patients) and radiotherapy (18 patients). Other anti-cancer drugs were concomitantly given to 85 patients. Sixty-four (75.3%) of 85 patients received gemcitabine and TS-1 2 ). Concomitant therapy was given to 40 patients (33.3%); the most common were bile-duct drainage (34 patients) and radiotherapy (5 patients). Other anti-cancer drugs were concomitantly given to 41 patients, of whom 30 patients received TS-1. 
SAFETY
ADVERSE DRUG REACTIONS
Common adverse drug reactions are shown in Table 3 . Adverse drug reactions occurred in 49.6% of patients, including serious adverse drug reactions occurring in 16.5%. Common adverse drug reactions (serious) were decreased white blood cell count occurring in 17.7% (3.5%) of the patients; decreased platelet count, 15.4% (2.7%); decreased neutrophil count, 11.5% (4.2%); pyrexia, 4.6% (1.2%); rash, 3.5% (0.4%); cholangitis, 2.7% (1.2%); malaise, 2.7% (0.8%); anaemia, 2.7% (0.4%); nausea, 2.3% (0.0%) and decreased haematocrit, 1.9% (0.0%).
Cholangitis assessed as causally related to gemcitabine was observed in seven patients (2.7%). The incidence of cholangitis in this survey was higher than that in the drug use-results survey of gemcitabine for non-small-cell lung cancer (0%). However, given that cholangitis is a common condition among patients with BTC, the higher incidence of cholangitis in this survey seemed likely associated with progression of the primary disease. In five of the seven patients who had cholangitis, worsening of the primary disease, liver metastasis or drainage obstruction was noted. The outcome of all seven patients was recovered or recovering.
Interstitial lung disease was reported in four patients (1.5%). This was comparable with 1.7% (36/2110 patients) incidence rate observed in the drug use-results survey of gemcitabine for non-small-cell lung cancer. The time to onset from the start of gemcitabine therapy was 23 -106 days. Of the four patients, one patient recovered without any corrective treatment, and the remaining three patients recovered or improved after steroid therapy.
ADVERSE DRUG REACTIONS IN ELDERLY PATIENTS
Adverse drug reactions are summarized separately for elderly and non-elderly patients in Table 3 . Adverse drug reactions occurred in 48.3% of elderly patients, and serious adverse drug reactions occurred in 20.8%. In non-elderly patients, adverse drug reactions occurred in 50.7%, and serious adverse drug reactions occurred in 12.9%. Importantly, this shows that the incidence of serious adverse drug reactions was higher in elderly patients. However, there were no differences in reported adverse drug reactions between the elderly and the non-elderly.
In elderly patients, the adverse drug reactions that occurred three or more times in a single patient were: decreased white blood cell count in 15.8% (serious: 3.3%) of the patients; decreased platelet count, 15.0% (3.3%); decreased neutrophil count, 10.8% (5.0%); pyrexia, 3.3% (0.0%); rash, 3.3% (0.0%); cholangitis, 2.5% (0.8%); malaise, 3.3% (1.7%); anaemia, 3.3% (0.0%) and decreased haematocrit, 2.5% (0.0%). Table 4 presents a summary of hepatic laboratory test abnormalities.
LIVER FUNCTION TESTS
Hepatic laboratory abnormalities !Grade 3 were observed in 104 patients. Of these, 73 patients had worsening of the primary lesion or liver metastasis, and 40 patients had drainage obstruction including overlapping.
Serious worsening of test values occurred in 36.7% (44/120) of elderly patients, compared with 42.9% (60/140) of non-elderly patients. Thus, the incidence of serious 1048 Post-marketing surveillance of gemcitabine with 260 Japanese BTC patients abnormalities in liver function test values in elderly patients was not higher than that in non-elderly patients. Table 5 shows hepatic laboratory abnormalities !Grade 3 with/without pre-existing hepatic dysfunction at baseline. Sixty-five patients without pre-existing hepatic dysfunction at baseline had !Grade 3 hepatic laboratory test abnormalities. Of these, 44 patients had worsening of the primary lesion or liver metastasis and 22 patients had drainage obstruction including overlapping. On the other hand, 39 patients with pre-existing hepatic dysfunction at baseline had !Grade 3 hepatic laboratory test abnormalities. Of these, 29 patients had worsening of the primary lesion or liver metastasis, 18 patients had drainage obstruction including overlapping. REASON FOR DISCONTINUATION Table 6 shows the details of treatment discontinuation. In the safety analysis set (260 patients), gemcitabine therapy was discontinued in 224 patients 12 months after the starting of gemcitabine treatment: 36 patients continued beyond 12 months. The most common reason for discontinuation was progression of disease in 118 patients, followed by adverse event onset in 35 patients, transfer to another hospital in 29 patients, patient's request in 23 patients, cancer death in 12 patients, change to another therapy in 16 patients, completion of planned therapy in 16 patients and other reasons in 4 patients. As for the survival status at 12 months from the start of therapy, 103 patients were alive and 141 patients were dead, while the survival status was unknown or not recorded for 16 patients. The cause of death was cancer progression in 137 patients and other disease or accident in 4 patients.
EFFECTIVENESS
SURVIVAL TIME Table 7 shows the estimated median survival time and 1-year survival rate. The estimated 1-year survival rate was 79.8% [95% confidence interval (CI), 67.1 -88.0%] in those given gemcitabine for post-operative adjuvant chemotherapy, 61.2% (95% CI, 44.0 -74.6%) in those given gemcitabine for post-operative recurrent BTC and 37.2% (95% CI, 28.5 -45.9%) in those given gemcitabine for unresectable BTC. In addition, 1-year survival rates in the non-bile-duct drainage and bile-duct drainage groups was 62.5 vs. 41.1% (95% CI, 53.4 -70.2% vs. 95% CI, 31.9 -50.1%), respectively. The reasons for gemcitabine treatment in the bileduct drainage group were as follows: unresectable BTC: 64.7%, post-operative adjuvant chemotherapy for BTC: 16.0%, post-operative recurrent BTC: 7.6% and post-non-curative resection of BTC: 7.6%. The respective percentages in the non-bile-duct drainage group were 39.0, 31.2, 24.1 and 5.7%. Figure 2 shows Kaplan -Meier survival curves of the adjuvant group and the advanced/recurrent group.
CEA AND CA19-9
Decreased CEA was observed in 54.8% (17/31) patients; CEA decreases of 50% or more were observed in 35.5% (11/31) patients. Decreased CA19-9 was observed in 71.3% (72/101) patients, with decreases of 50% or more observed in 49.5% (50/101) patients.
DISCUSSION
In the Japanese Phase II study (BT-21) of single agent gemcitabine in patients with advanced BTC (3), common adverse drug reactions included myelosuppression (decreased white blood cell count, decreased neutrophil count and decreased haemoglobin), hepatotoxicity (increased ALT and increased g-GTP), anorexia, nausea, vomiting, fatigue and constipation. In this survey, adverse drug reactions occurred in 49.6% of the patients, which were lower than that observed in BT-21. Data were collected differently in the PMS study and the BT-21 clinical trial. All PMS data were collected under a clinical setting, so that the frequencies of observation and laboratory examinations could be fewer and more irregular than those of the clinical study. Furthermore, data collected for PMS were based on each investigator's decision; the types of data collected were not specified as with sponsor-conducted monitoring in clinical trials.
Adverse drug reactions commonly reported in this survey included myelosuppression, such as decreased white blood cell count, pyrexia, cholangitis, malaise and nausea. Overall, these were consistent with the previously known safety profile for gemcitabine. The incidence of cholangitis was higher than that in the previous post-marketing surveys of gemcitabine for non-small-cell lung cancer or pancreatic cancer (7); however, given that cholangitis is a common condition among patients with BTC, cholangitis seemed likely associated with the primary disease itself. Interstitial lung disease was reported in 1.5% (4/260) patients, but this was not higher compared with the previously reported incidence rate in the post-marketing surveys for non-squamous cell lung cancer (7). Three cases had about 3-4 months discontinuation of gemcitabine treatment. Regarding liver dysfunction, detailed analyses were conducted with a focus on the change in liver function test values. As shown in Table 4 , about three-fourths of the cases of worsened hepatic dysfunction during gemcitabine therapy were considered related to the progression of the primary disease or drainage obstruction. While it is generally known that patients with BTC often have concurrent hepatic dysfunction, in this survey concurrent hepatic dysfunction was reported by the attending physicians in 27.7% (72/260) patients. Comparing the incidence of hepatic laboratory abnormalities !Grade 3 with the presence/absence of preexisting hepatic dysfunction at baseline showed that 54.2% of patients with laboratory abnormalities had pre-existing hepatic dysfunction at baseline. This was a higher percentage than 34.6% of those who had no pre-existing hepatic dysfunction at baseline. Clearly, gemcitabine therapy should be conducted more carefully if there is evidence of hepatic dysfunction.
Because of the limited number of elderly patients (aged 70 years and older) evaluated in the original BT-21 study (3), the data from elderly patients were a particularly important focus during the evaluation of the survey results. In elderly patients, adverse drug reactions occurred in 48.3%, and serious adverse drug reactions in 20.8%. In non-elderly patients, adverse drug reactions occurred in 50.7%, and serious adverse drug reactions in 12.9%. Thus, the incidence of serious adverse drug reactions was likely to be higher in the elderly. However, for each event, no notable difference in incidence was observed between elderly and non-elderly patients. Discontinuations due to AEs were observed in 13.5% (35/260), of which 18.3% (22/120) of elderly patients discontinued compared with 9.3% (13/140) of non-elderly patients. Given these results, careful attention to the toxicity of gemcitabine should be a general consideration of cancer care in elderly patients.
Survival data were analysed to evaluate effectiveness. In the Japanese Phase II study of gemcitabine monotherapy in patients with BTC, the response rate was 17.5%, and the median overall survival (OS) was 7.6 months (3). These results were more favourable compared with those of uraciltegafur (UFT) and doxorubicin, i.e. drugs that had been commonly used for the treatment of BTC. In this survey, the median OS in all patients was 378 days (95% CI, 333 -414 days), longer than that of the clinical trial, but this survey was conducted under conditions of routine clinical practice and included patients given the drug for post-operative adjuvant chemotherapy. After the exclusion of patients who were given the drug for post-operative adjuvant chemotherapy, the median OS was 310 days (95% CI, 263 -371 days). This is longer than the median OS in BT-21. However, a direct comparison cannot be made because of differences in patient backgrounds, such as the number of patients with metastasis of lymph nodes, liver and/or other sites. Additionally, in this survey, 32.7% of patients had been treated with anti-cancer drugs, and there were 18 cases where radiotherapy was used concomitantly with gemcitabine. Considering these differences, the survival data from PMS looked consistent with the data in the BT-21 study and supports the efficacy data obtained with gemcitabine monotherapy.
Survival times in the subgroup with bile-duct drainage were shorter than in the non-bile-duct drainage group. The difference in survival data between the two subgroups might be due to differences in patient background. While two-thirds of patients in the bile-duct drainage group had unresectable disease, over half of patients in the non-bile-duct drainage group were receiving adjuvant therapy or had post-operative recurrent disease. After initiating this survey, further attempts to enhance the efficacy of gemcitabine in BTC by combining it with cisplatin were made in both a global Phase 3 study (ABC-02) and the Japanese Phase 2 study (BT-22). The results of these two studies have now been reported (9, 10) .
Gemcitabine-based concomitant therapies have been the main treatment of choice for combination therapy in BTC treatment. In a randomized Phase II UK study that compared gemcitabine alone vs. gemcitabine plus cisplatin (GC), the gemcitabine monotherapy group showed a response rate of 22.6% and a median progression-free survival (PFS) of 4 months, whereas the GC group showed a response rate of 27.8% and median PFS of 8 months, thereby indicating the usefulness of this combination therapy (8) . Subsequently, a large-scale Phase III study (Study ABC-02) was conducted, which indicated significantly prolonged survival in the GC group compared with the gemcitabine monotherapy group, without any profound differences in adverse events between the two groups (9) . Also in Japan, a randomized comparative study conducted using the same regimen as Study ABC-02 demonstrated similar results (10) . These results indicate that GC therapy has the potential to become a novel global standard therapy for novel treatment unresectable BTC.
In this survey as well, treatment with gemcitabine in routine clinical practice demonstrated the efficacy and acceptable safety in patients with BTC. The results of this survey did not show any new safety concerns in elderly subjects and supports the results of the Phase II study of gemcitabine monotherapy conducted in Japan.
